
==== Front
Clin Exp Pediatr
Clin Exp Pediatr
CEP
Clinical and Experimental Pediatrics
2713-4148
Korean Pediatric Society

38810986
10.3345/cep.2023.01697
cep-2023-01697
Review Article
Developmental and Behavioral Medicine
Comprehensive evaluation of the child with global developmental delays or intellectual disability
http://orcid.org/0009-0002-8343-9723
Aldosari Abdullah Nasser MD 1
http://orcid.org/0009-0005-1231-3746
Aldosari T. Saeed BEd 2
1 Department of Pediatrics, King Fahad Hospital, Al Baha, Saudi Arabia
2 Department of Special Education, Prince Sattam bin Abdulaziz University, Riyadh, Saudi Arabia
Corresponding author: Abdullah Nasser Aldosari, MD. Department of Pediatrics, King Fahad Hospital, Al Baha 65732, Saudi Arabia Email: Dr.anad@outlook.sa
9 2024
29 5 2024
67 9 435446
8 12 2023
9 3 2024
7 4 2024
Copyright © 2024 by The Korean Pediatric Society
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Global developmental delay (GDD) and intellectual disability (ID) are relatively common neurodevelopmental disorders that significantly impact affected children, their families, and society. The etiology of GDD/ID is notably diverse, encompassing both genetic and acquired factors. Although the precise cause of most GDD/ID cases remains unclear, an estimated half of all cases can be attributed to genetic factors. Thus, a detailed medical history and comprehensive physical examination remain pivotal for guiding diagnostic investigations into the underlying causes of GDD/ID. Advancements in genetic testing have supplanted traditional methods such as karyotyping and fluorescence in situ hybridization with chromosomal micro arrays, which are now the primary genetic tests for children with idiopathic GDD/ID. Moreover, the evaluation of Fragile X and Rett syndrome should be an integral component of initial diagnostic assessments. In recent years, whole-exome sequencing and whole-genome sequ-encing have emerged as important diagnostic tools for evaluating children with GDD/ID and have substantially enhanced the diagnostic yield rates. Gene therapy has emerged as a promising avenue and is poised to become a cornerstone in addressing various genetic developmental and epilepsy disorders. Early intervention facilitated by a proficient multidisciplinary team can markedly enhance the prognosis and outcomes of GDD/ID, particularly when parents or caregivers are actively engaged in the interventional process. This review discusses risk factors and common underlying causes, explores recent evidence and recommendations for genetic evaluation, and offers management strategies for children with GDD/ID.

Global developmental delay
Intellectual dis-ability
Genetic testing
Next-generation sequencing
Child
Key message

· A detailed history and comprehensive physical examination remain the cornerstones for establishing a diagnosis of global developmental delay/intellectual disability (GDD/ID).

· Comprehensive surveillance and screening programs play a significant role in the early detection of GDD.

· Whole-exome sequencing is highly recommended as first- or second-line testing for individuals with idiopathic GDD/ID.

· Early intervention by a well-versed multidisciplinary team can significantly improve the outcomes and prognosis of GDD/ID.
==== Body
pmc

Graphical abstract. Algorithm for investigating of child with GDD/ID. GDD, global developmental delay; ID, intellectual disability; EEG, electroencephalography; MeCP2, methyl-CpG binding protein 2; FISH, fluorescence in situ hybridization; CT, computed tomography; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; WES, whole-exome sequencing; WGS, whole-genome sequencing.

Introduction

Developmental delay (DD) is among the most prevalent chronic medical conditions encountered in general pediatric, neurological, and genetic clinics. DD refers to one's inability to achieve developmental milestones within an anticipated timeframe across one or more domains including motor skills, language, cognition, social interaction, emotional development, and adaptive functioning [1]. DD can manifest as isolated delays within a specific domain or as global DD (GDD), which is characterized by delays equal to 2standard deviations below the mean in 2or more developmental domains among children under 5 years of age [1]. Furthermore, DD can exhibit transient features, particularly in cases of chronic illness, or persist, potentially culminating in developmental disabilities [2].

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines intellectual disability (ID) as one of several neurodevelopmental disorders (NDDs) that begin in childhood. ID is characterized by deficits in intellectual functioning (problem-solving, reasoning, academic learning, planning, abstract thinking, judgment, and learning from experience) and difficulties in adaptive functioning (competence in social, conceptual, and practical skills) [1]. NDDs are a group of cognitive and behavioral disorders that become apparent in early childhood and are characterized by evident impairments or limitations in personal, academic, social, or occupational functioning. This category encompasses GDD and ID as well as other conditions such as cerebral palsy (CP), autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), learning disabilities, developmental language impairments, and developmental coordination disorder [1]. The overall prevalence of DD and ID varies and is influenced by numerous factors including socioeconomic status, environmental conditions, and assessment methodologies.

Community-based studies conducted in various countries reported that the prevalence of DD in children is 10%–15%, whereas GDD affects approximately 1%–3% of children. ID affects an estimated 1%–3% of school-aged children, with approximately 85% of cases classified as mild, and many individuals in this category even achieve academic success [2,3]. Several studies have suggested that a family's medical history could play a role in GDD, ID, and NDDs, especially when other family members are similarly affected. These conditions may encompass genetic or chromosomal abnormalities such as Down syndrome or Fragile X syndrome as well as NDDs such as ADHD and ASD. Although the precise prevalence of GDD/ID within families remains uncertain, various studies reported rates of 12.5%–22.5% [2,4,5].

DD does not always signify a developmental disability. However, it can serve as an early indicator of learning disabilities, and many children with disabilities encounter various DDs. DD severity is typically categorized as mild, moderate, or severe based on functional age as assessed by a developmental pediatrician using age-appropriate standardized measures of function and development compared with chronological age (i.e., mild, 67%–100%; moderate, 33%–66%; severe, <33%) [2,6]. Intellectual functioning is commonly evaluated using intelligence quotient (IQ), with an average of 100. Children with ID typically exhibit IQ scores <70 (2 standard deviations below the average) [7]. However, not all children with GDD have concurrent deficits in intellectual functioning. Research indicates that approximately 20% of preschoolers with GDD demonstrate average intellectual functioning [8]. It is important to recognize that not all children with GDD develop ID later in life. Developmental disorders such as CP are frequently associated with notable delays in motor skills, speech, and cognition. Nevertheless, some individuals may demonstrate average intelligence [9].

GDD/ID has various causes that are typically categorized into acquired and genetic. Although the exact cause is often unknown, genetic factors contribute to approximately half of all cases [2,10]. Genetic testing has become an essential component of the diagnostic evaluation. The early identification of warning signs and underlying causes, along with the implementation of appropriate management strategies, is crucial for predicting the patient's clinical course, enhancing their intellectual functioning and developmental skills, and providing accurate prognostic counseling. This study aimed to review the risk factors, etiologies, diagnostic approaches (including available genetic tests and their results), and management strategies for children with GDD/ID.

Risk factors and etiologies

Multiple risk factors contribute to GDD/ID, including premature birth, low birth weight, perinatal complications, chronic illness, chronic malnutrition, low socioeconomic status, and a lack of appropriate care [11]. GDD/ID has a heterogeneous etiology that encompasses both acquired and genetic causes. Although the etiology of most GDD/ID cases is unknown, a genetic origin is responsible for up to 50% of cases. Down syndrome is the most common chromosomal abnormality associated with GDD/ID, whereas Fragile X syndrome is the most prevalent genetic disorder. Other possible causes include Rett syndrome,Angelman syndrome, Williams syndrome, Prader-Willi syndrome, and subtle translocations or deletions in genetic material [12,13].

Metabolic disorders represent a relatively uncommon etiology of GDD/ID, comprising only approximately 1%–5% of cases. Furthermore, they typically involve multiple organ systems and manifest as acute decompensation or regression of developmental milestones rather than mere delays. However, it is imperative to consider metabolic disorders such as congenital hypothyroidism, phenylketonuria, and methylmalonic acidemia as potential underlying causes of GDD/ID [14,15]. In addition to central nervous system malformations, brain injury leading to neurodevelopmental disabilities can stem from pre- and postnatal complications such as asphyxia, congenital and acquired infections, kernicterus, and head trauma [16,17]. Uncontrolled maternal medical conditions and environmental exposure during pregnancy can precipitate GDD/ID. Such exposures may include the maternal consumption of alcohol, opioids, and teratogenic medications [18,19]. Premature infants or those with nutritional deficiencies, chronic illness, familial stress, immaturity, or prolonged hospitalization may experience transient DDs [2]. Table 1 lists the most common causes of GDD/ID [2,5,12-19].

Diagnostic approach

Developed countries have well-established healthcare systems that employ comprehensive surveillance and screening programs to facilitate the early recognition and intervention and improve the outcomes of children with GDD/ID. Clinicians must be familiar with the normal developmental milestone ranges and the evolving maturation process to promptly recognize delays [20]. Moreover, it is important to adjust the chronological ages of premature infants to appropriate milestones by considering their corrected gestational ages. The diagnosis of GDD/ID requires an intellectual assessment, adaptive evaluation, audiometry, vision testing, and psychiatric and behavioral assessments [2].

Several intelligence tests have been developed to assess mental abilities, including abstract thinking, learning, and problem-solving in novel situations. Commonly utilized tests include the Wechsler scale, Stanford-Binet Intelligence Scale, and Differential Ability Scales. The IQ score is frequently used to compare an individual's intellectual capacity to the average score of a comparable group. Based on IQ score, individuals can be categorized into different ID levels: Mild ID (IQ 50–70) is the most prevalent, accounting for 85% of cases, followed by moderate ID (IQ 35–50), which is observed in 10% of cases, and severe ID (IQ 20–35), which is present in 4% of cases. Profound ID (IQ <20) is the least common, occurring in only 1% of cases [7,21]. The diagnostic process for GDD/ID typically commences with a thorough clinical history, comprehensive physical examination, and behavioral assessment, which requires further investigation.

1. History and physical examination

A thorough clinical history and physical examination are essential to diagnostic accuracy, as they can reveal the underlying cause of the disorder in up to 38.6% of cases [22]. To ensure diagnostic accuracy, it is crucial to gather detailed information about the patient's gestation, prenatal and perinatal events, delivery mode, neonatal care, developmental milestones, medical history, psychosocial background, maternal health, consanguinity, and three-generation family history. A meticulous neurodevelopmental assessment may also provide additional insight into the common causes of GDD/ID, including the evaluation of developmental milestones across all domains, growth parameters, and neurological findings.

Growth parameters (especially head circumference) should be plotted on appropriate growth charts and compared with previous measurements and with those of other family members [2,7,12,17]. The presence of dysmorphic features indicates specific genetic syndromes. However, in some children with dysmorphic features and/or malformations with or without GDD/ID, a detailed history and comprehensive examination may not immediately suggest a diagnosis. Therefore, the test should be conducted by a trained clinical geneticist, particularly in cases with subtle findings that are often important for the differential diagnosis. An essential component of the dysmorphological examination is observation of the patient from head to toe as well as a comparison with established normative values and photographs of the parents and siblings. Many children with dysmorphic features have DD, malformations, or both. A large study of individuals with NDDs identified dysmorphic features in approximately 47% of cases [23].

Various syndromes with distinct dysmorphic features can also result in GDD/ID; thus, clinicians must be knowledgeable and acquainted with these conditions. Fragile X syndrome, among the most prevalent of these syndromes, is characterized by identifiable clinical features that are easily noted in affected males with the full mutation. These features encompass dysmorphic facial characteristics (large ears, elongated faces, pronounced jaws, macrocephaly, hyperextendable joints, soft skin, and hypotonia) along with macroorchidism. However, these features may be subtle, particularly in females or prepubertal males.

Furthermore, Rett syndrome, an X-linked dominant disorder that affects primarily girls, demonstrates variable clinical manifestations marked by a progressive cognitive decline, loss of purposeful hand function accompanied by stereotypical hand movements (such as clapping, wringing, and tapping), speech and language impairments, acquired microcephaly, and progressive lower-limb spasticity. Breathing abnormalities such as breath-holding, hyperventilation, and air swallowing are commonly observed. Additionally, gait apraxia, kyphoscoliosis, sleep disturbances, episodes of laughter and cream, and a reduced response to pain are other variable characteristics of this disorder [2,12,23,24].

Anomalies affecting the musculoskeletal system, eyes, heart, genitourinary tract, and connective tissues may also be discerned during routine systemic physical examinations, potentially those indicating a specific diagnosis or guiding laboratory investigations. Behavioral assessment provides the basis for describing any atypical pattern of a child’s behavior, such as aggression, repetitive and self-injurious behavior, decreased social engagement, and impulsivity. Table 2 outlines the essential points of history taking and physical examination.

2. Biochemical and metabolic investigations

In addition to paying careful attention to resource utilization and risk-benefit analyses, laboratory evaluations should be carefully selected. Given that many cases of GDD/ID are idiopathic and significant or pathognomonic findings in laboratory tests are uncommon, it is imperative that tests be conducted judiciously to prevent unwarranted investigations [7,22]. In developed countries, all newborns undergo screening programs at birth that encompass critical cardiac diseases, hearing loss, and a spectrum of inheritable disorders related to metabolic, hematologic, endocrine, and other conditions. Consequently, it is inadvisable to conduct these screening tests in children with GDD/ID unless a specific underlying cause is indicated by their medical history or physical examination findings [25].

An initial assessment may include routine complete blood count, electrolytes, basic chemistry and lipid panels, iron, creatinine kinase, thyroid function, and liver function tests. A thorough investigation of inborn errors of metabolism may involve plasma amino acids, ammonia, lactic acid, serum lactate/pyruvate, urine organic acids, capillary blood gases, and lysosomal enzymes. Additional tests, if warranted, could encompass uric acid levels, very long-chain fatty acids, transfer, copper, ceruloplasmin, and acylcarnitine levels. A routine urinalysis is performed to detect oligosaccharides, glycosaminoglycans, sialic acids, urine purines, urea, and pyrimidines. A cerebrospinal fluid analysis is not recommended for the routine evaluation for GDD/ ID. However, specific indications including glucose, lactic acid, glycine, and pyruvate may be considered.

Screening for congenital infections (e.g., Toxoplasma, rubella, cytomegalovirus, hepatitis B virus, human immunodeficiency virus,herpes virus) may also be warranted in cases with symptoms of microcephaly, neurological anomalies, and hearing or vision loss. Screening for lead toxicity should focus on children with identifiable risk factors for environmental exposure. Furthermore, more comprehensive testing for specific diseases is typically justified once the results become available [2,7,10,12,17].

3. Neuroimaging and electroencephalography

Although routine neuroimaging studies are not recommended for assessing children with unexplained GDD/ID, their use may lead to the recognition of a specific cause, particularly in children who present with dysmorphic features or focal neurological findings [26]. Brain magnetic resonance imaging (MRI) has a varied diagnostic yield of 47%–72% depending on the use of newer techniques and additional clinical findings. MRI is more sensitive than computed tomography at detecting clinically relevant structural abnormalities and anomalies related to myelination and neuronal migration, resulting in a higher diagnostic yield [26,27]. Electroencephalography may play an important role in the assessment of children with GDD/ID, as it helps clinicians classify and evaluate seizures and identify specific epileptic syndromes, such as acquired epileptiform aphasia syndrome and electrical status epilepticus, during slow-wave sleep. However, its use is not routinely recommended as part of the initial evaluation unless there are historical features suggestive of epilepsy, a specific epileptic syndrome, or speech regression [12].

4. Genetic testing

Genetic disorders and congenital anomalies contribute significantly to childhood mortality, morbidity, and lifelong disabilities. Over the past three decades, advances in genetics have revolutionized human health by introducing novel testing approaches to facilitate diagnosis, treatment, therapy, improved outcomes, preventive screenings, and population-based risk assessments. Notably, up to 80% of rare disease cases have identifiable genetic origins, underscoring the pivotal role of genetic tests and their impact on patients, families, and the healthcare system [28,29]. Table 3 summarizes the recent studies that highlighted the genetic significance of assessing individuals with GDD/ID and NDDs [30-45].

1) Chromosome microarray analysis

Genetic etiologies, including chromosomal abnormalities (e.g.,microdeletions,microduplications, and trisomies),have been proposed to account for approximately half of GDD/ID cases [2,10]. Copy number variations, genetic deletions and duplications, and encompassing insertions are important contributors to human genetic diversity and sources of associated genetic mutations. The enhanced sensitivity of microarray-based genomic copy number analysis enables the detection of submicroscopic deletions and duplications, resulting in a significantly higher diagnostic yield than that of karyotyping (15% vs. 7.4%, respectively). Thus, it has become a standard diagnostic genetic test for patients with unexplained GDD, ID, ASD, epilepsy, or multiple congenital anomalies. Furthermore, it is the most effective diagnostic tool for evaluating GDD/ID after a thorough history and comprehensive physical examination [46-48].

In one study, a chromosome microarray analysis (CMA) was performed in patients with normal karyotype results, resulting in a diagnostic yield of 21.7% (18 of 83) [30]. Two CMA platforms were used to analyze chromosome array comparative genomic hybridization and single-nucleotide variant arrays. These platforms are utilized to visualize and detect chromosomal copy number variants, including genomic gains (microduplications) and losses (microdeletions), with a higher resolution for genomic imbalances than conventional G-banded karyotypes. However, CMA has limited ability to detect low-level mosaicism and cannot detect balanced chromosomal rearrangements [49,50].

Patients with both syndromic and nonsyndromic GDD/ID can exhibit a wide range of phenotypic features caused by various microdeletions and duplications. Some examples of such syndromes include Prader-Willi and Angelman syndromes (deletion of 15q11-q13), Smith-Magenis syndrome (deletion of 17p12), Williams-Beuren syndrome (deletion of 7q11.23), and deletions in the CHRNA7 and SH2B1 genes, among others [2,7,10,12]. Interpreting variants of uncertain significance identified by CMA can be challenging, particularly when identifying incidental findings, such as the deletion of cancer predisposition genes such as FLCN or BMPR1A, which can have significant ethical implications, especially when investigating GDD/ID. Therefore, it is recommended that the interpretation of abnormal results and variants of unknown significance in the CMA test and subsequent counseling of families be performed by a medical geneticist and certified genetic counselor in collaboration with the reference laboratory and platform used. This will ensure that the interpretation is accurate and appropriate counseling is provided to families [51].

2) Chromosomal karyotyping

Karyotyping is considered the first standard diagnostic test for children with GDD/ID for over 35 years. However, it has been replaced by CMA, which can perform a similar function at much higher resolution for genomic imbalances, thus substantially increasing sensitivity. Although karyotyping has the limitations of low resolution and a detection rate of approximately 7.4% for evaluating patients with unexplained GDD/ID, it has been recommended instead of CMA in cases of clinically suspected aneuploidy (e.g., Down syndrome, Turner syndrome), multiple spontaneous abortions, refractory epilepsy, and a family history of chromosomal rearrangements [30,48].

3) Fragile X and rett syndrome testing

Fragile X syndrome is an X-linked trinucleotide expansion disorder caused by the unstable expansion of a CGG triplet repeat sequence in the FMR1 gene on Xq27.3. Fragile X syndrome is the most common genetic abnormality associated with ID and the most common monogenic cause of ASD [52]. The prevalence of Fragile X syndrome varies among individuals with GDD/ID. An estimated 2.2%–2.5% of affected individuals with GDD/ID caused by Fragile X syndrome are boys, whereas 1.3%–1.6% are girls [50]. Although Fragile X syndrome may occur in both males and females, its distinctive clinical features are most easily recognized in males with the full mutation. However, this effect may be subtle or apparent only upon puberty [52].

The diagnostic yield of Fragile X testing among patients with NDDs varies widely depending on factors such as the characteristics of the population being tested, study design, and sex. This yield is estimated to be 1.2%, with significantly higher rates observed when testing is restricted to males exhibiting NDD-consistent physical and behavioral phenotypes, particularly in the presence of a positive family history [53]. Fragile X should be strongly considered and recommended as part of first-line investigations in both boys and girls with GDD/ID and/or ASD, especially in the presence of a positive family history, consistent physical and behavioral phenotype, and the absence of major structural abnormalities. Use of the X-linked ID panel may be appropriate for patients with a family history of X-linked inheritance and normal microarray, chromosomal, or Fragile X results [2,7,12,53].

Rett syndrome is a rare and severe NDD that almost exclusively affects girls and is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MECP2) on the long arm of the X chromosome (Xq28) [54]. A recent meta-analysis estimated the global prevalence of Rett syndrome as 7.1 cases per 100,000 female individuals [55]. Rett syndrome has variable clinical expressions but is characterized by progressive cognitive impairment, speech and language disabilities, decelerated head growth (acquired microcephaly), and loss of purposeful hand use, which is often replaced with stereotypic hand movements [54]. In contrast, mutations of MECP2 in boys may result in severe neonatal encephalopathy [56]. Notably, some patients with Rett syndrome do not harbor mutations in the MECP2 gene. Interestingly, others with mutations in the MECP2 gene do not have the classical clinical features of Rett syndrome [57]. However, when Rett syndrome is clinically suspected, a molecular analysis should be performed.

4) Next-generation sequencing

Next-generation sequencing (NGS) effectively identifies novel gene mutations and discrete genomic variations, hence increasing the genetic diagnostic yield of GDD/ID [58]. Whole-exome sequencing (WES) can be used concurrently to interpret the DNA sequences of thousands of protein-encoding genes using NGS techniques. WES is proven helpful in patients with multiple genetic conditions, atypical presentations of a genetic disorder, and early presentations of a disease for which classic findings are lacking. However, WES has important limitations, one of which is incomplete exome coverage, which does not allow for the examination of all exons potentially affecting the test yield. Moreover, WES does not reliably detect mosaic variants, repetitive sequences, exon-level deletions, epigenetic variants, or balanced rearrangements [59]. In a recent meta-analysis focusing on isolated NDDs, the estimated diagnostic yield of WES was 31%, greater than that of CMA (15%). Higher yields were observed in patients with abnormal head size, younger age at presentation, and developmental epileptic encephalopathy [49]. According to the 2021 American College of Medical Genetics and Genomics guidelines, WES is highly recommended as a first- or second-line test for children with GDD/ID [49,60].

Whole-genome sequencing (WGS) is an NGS approach that enables the in-depth analysis of entire genomes, including exons, noncoding DNA, and structural variants. WGS is unavailable for clinical use in most medical centers and restricted to clinical research. According to a recent review, the diagnostic yield of WGS in cases of GDD/ID is 21%–64% [31]. In a clinically heterogeneous cohort, WGS as the main clinical test provided a greater diagnostic success rate than conventional genetic testing [61]. Overall, compared to WES, extrapolation of the additional information by WGS was estimated to improve the diagnostic rate of WES by 9%–15% [62]. Certain genetic disorders are not evident at birth or during the first few years of life. Thus, continued follow-up by geneticists and an NGS reanalysis every 1–3 years are recommended to enhance the diagnostic yield by incorporating new disease gene discoveries, additional phenotypic information becoming available over time, variant reclassification, and improved bioinformatics pipelines. The diagnostic benefits of a periodic WES and WEG data reanalysis have shown improvements in diagnostic yield of 12.6% and 10.9%, respectively, in individuals with NDDs [63,64].

5. Hearing and visual assessments

Since children with GDD/ID are more susceptible to visual and hearing abnormalities, it is crucial to provide them with a comprehensive ophthalmological assessment, including a dilated funduscopic examination and vision screening. Furthermore, behavioral observation audiometry and brainstem auditory-evoked responses are recommended, particularly for children exhibiting speech and language delays or autistic characteristics [65-67]. Table 4 outlines the essential investigations for evaluating individuals with GDD/ID.

Management and outcome

The primary principle in managing individuals with GDD/ID is early intervention, which not only enhances their developmental functioning and potential but improves their quality of life and social participation [68]. Providing multidisciplinary services and implementing structured school and home exercise programs can positively impact the psychosocial well-being of children and their caregivers [67]. Numerous studies have shown that involving parents or caregivers in early interventions leads to functional improvements in individuals with NDDs [69,70]. Individuals with GDD/ID may have various physical, behavioral, and mental-health comorbidities, including epilepsy, vision and hearing impairments, ADHD, aggressive or self-injurious behavior, sleep disturbances, obstructive sleep apnea, recurrent chest infections, malnutrition, constipation, gastroesophageal reflux disease, movement disorders, and orthopedic deformities [71,72]. Individuals with GDD/ID must be evaluated by a multidisciplinary team that is familiar with these disorders and their associated complications. Such teams may comprise pediatricians, neurologists, child and adolescent psychiatrists, developmental and behavioral pediatricians, audiologists, ophthalmologists, speech therapists, physical therapists, occupational therapists, orthopedic surgeons, and other relevant pediatric subspecialists as required [73,74].

Although no specific medical therapy is available for most of GDD/ID cases, certain instances can be reversible or treatable if identified promptly and managed effectively. These include acquired and inherited metabolic disorders such as homocystinuria, methylmalonic aciduria, biotinidase deficiency, hypothyroidism, and nutritional deficiencies, among other conditions [75]. Furthermore, managing associated comorbidities such as epilepsy, spasticity, aggressive or self-injurious behavior, and sleep disorders may necessitate appropriate pharmacological interventions [76].

In recent years, gene therapy has emerged as a promising solution for addressing a variety of genetic, developmental, and epileptic disorders that can significantly affect an individual's cognitive and physical development. This innovative approach targets the underlying genetic causes of these conditions and often utilizes viral vectors to deliver corrected genes or gene editing tools directly into patient cells. For example, in disorders such as Rett syndrome and Fragile X syndrome, gene therapy has shown promising ability to improve motor and behavioral symptoms in animal models. However, challenges remain in determining optimal expression levels and mitigating the associated risks.

Alternative strategies, such as clustered regularly interspaced short palindromic repeats-mediated gene editing and antisense oligonucleotides, are being explored to address these challenges. Additionally, gene therapy approaches for disorders such as Angelman syndrome and Dravet syndrome aim to enhance specific gene activity to counterbalance genetic mutations. Clinical trials have demonstrated improved cognitive functions, motor skills, and overall quality of life in patients with genetic developmental disorders or epilepsy. Despite ongoing challenges related to safety, efficacy, and ethical considerations, the clinical application of gene therapy represents a significant advancement in personalized and transformative treatments for these complex conditions [77]. Finally, the early involvement of a geneticist can help with diagnostic confirmation, workup guidance, and genetic counseling. In some cases, social work and family support services can offer counseling, monetary, and educational support as well as connections to other support services to help families manage their child's condition.

Conclusion

Comprehensive surveillance and screening programs play a crucial role in the early detection of GDD/ID in children by facilitating interventions that can significantly enhance outcomes. Guidelines for evaluating children with GDD/ID are generally similar, commencing with a thorough history taking, followed by a comprehensive examination, which serves as the foundation for planning diagnostic investigations aimed at identifying the etiology. Genetic testing is a crucial and highly effective tool for diagnosing GDD/ID. However, it is essential to recognize that each genetic diagnostic method has its advantages and limitations, which necessitates careful consideration based on specific clinical scenarios.

It is imperative to acknowledge that there is no one-size-fits-all approach and that the decision-making process should prioritize clinical suspicion and the objectives of genetic testing. CMA is an established diagnostic test for children with unexplained GDD/ID. Nevertheless, WES and WGS have demonstrated greater effectiveness at identifying GDD/ID etiology, particularly in cases of complex clinical phenotypes or uncertainty regarding the underlying genetic cause. Consequently, they are now recommended as first- or second-tier approaches to examining unexplained GDD/ID. The clinical application of gene therapy represents a paradigm shift in the treatment of various genetic disorders including GDD/ID. By targeting the underlying genetic causes of these conditions, gene therapy offers the potential for improved outcomes and enhanced quality of life in affected individuals. As research progresses and technology evolves, gene therapy has become a cornerstone in the management of GDD/ID. Although most GDD/ID cases are incurable, early supportive management and therapies such as physical, speech, and occupational therapies are effective and should be encouraged to maximize the abilities of an affected child.

Table 1. Etiologies of global developmental delay and intellectual disability

Timing of exposure	Possible causes	Examples	
Prenatal	Genetic disorders/intrauterine growth retardation	Down syndrome, Fragile X syndrome, Rett syndrome, Angelman syndrome, and Prader-Willi syndrome	
Central nervous system malformations/cerebral dysgenesis	Holoprosencephaly, anencephaly, agenesis of corpus callosum, lissencephaly, and polymicrogyria	
Metabolic/inborn error of metabolism	Congenital hypothyroidism, phenylketonuria, and methylmalonic acidemia	
Congenital infection	Cytomegalovirus, toxoplasmosis, rubella, syphilis, varicella, herpes simplex, and zika	
Toxins/teratogens	Alcohol, valproate, and opioids	
Uncontrolled maternal medical conditions	Urinary tract infection, asthma, hypertension, and pregestational diabetes	
Perinatal	Hypoxic ischemic encephalopathy/intraventricular hemorrhage/prematurity	Asphyxia and birth injury	
Central nerve system infections	Meningitis and encephalitis	
Metabolic	Hypoglycemia and hyperbilirubinemia	
Postnatal	Brain injury	Head trauma, near drowning, and stroke	
Central nerve system infections	Meningitis and encephalitis	
Toxic substances	Lead toxicity	
Nutritional deficiencies	Iodine, vitamin B12, and thiamine	
Chronic illness/severe psychosocial deprivation/neglect	Chronic ear infection, and celiac disease	

Table 2. Key points in history taking and physical examination

History	
 Antenatal history	
  Maternal illness/infection/trauma/drug intake/toxins/teratogens (e.g., urinary tract infection-gestational diabetes, hypertension, alcohol, valproate)	
  Abortion or stillbirth	
  Periconceptional folic acid	
  In vitro fertilization conception	
  Regular screening (e.g., fetal scan findings)	
  Fetal movement	
  Twining	
 Perinatal history	
  Prematurity/birth injury	
  Mode of delivery/difficult delivery/resuscitation/ respiratory support/Apgar score/ growth parameters	
  Birth asphyxia	
  Central nerve system infections (e.g., meningitis and encephalitis)	
  NICU admission	
  Seizure	
 Neonatal history	
  Central nerve system infections (e.g., meningitis and encephalitis)	
  Prematurity-related complications	
  Congenital anomalies	
  Jaundice/kernicterus	
  Poor or difficult feeding/weak crying/recurrent chocking or aspiration	
  Seizure	
 Postnatal history	
  Central nerve system infections (e.g., meningitis and encephalitis)	
  Brain injury (e.g., head trauma, near drowning, stroke)	
  Developmental milestone/ Regression	
  Chronic illness/ Hospital admission	
  Feeding and eating problems (e.g., Nutritional deficiency/Pica)	
  Behavioral concerns/Sleep problems	
  Academic performance	
  Medications	
  Immunization	
 Family history	
  Consanguinity	
  Socioeconomic status	
  Neurometabolic disease or GDD/ID	
Physical examination	
 Growth parameters	
  Body mass index/Weight/Height/Head circumference	
 Inspection and observation	
  Behavioral/cognitive (e.g., restricted interests, hyperactivity, aggressive or repetitive behaviors, poor eye contact, cooperation, understanding and following the commands)	
  Speech/language (e.g., fluent speech, dysarthria mutism)	
  Obvious abnormal movements (e.g., hand flapping, chorea, dystonia)	
  Pigmentary skin change (e.g., Café-au-lait spots, port wine stain, ash leaf spots)	
  Skeletal system deformities (e.g., stippling of the patella, scoliosis, myelomeningocele, short-limbed dwarfism, chest deformity, syndactyly, single palmar creases)	
 Dysmorphisms	
  Hair/skull shape (e.g., kinky, brittle, or colorless hair, wide anterior fontanelle, prominent forehead, craniosynostosis)	
  Face (e.g., coarse, myopathic, or elongated face, micro-macrognathia, long and thick eyebrow)	
  Eyes/eyelid (e.g., hypertelorism, strabismus, nystagmus, glaucoma, iris hamartoma, slanted, or deep-set eyes)	
  Ears (e.g., large, protruding, or low-set ears)	
  Nose (e.g., flat nasal bridge, upturned nares)	
  Mouth/tongue/teeth/palate (e.g., fish mouth, tongue fasciculation or protruding, gapped teeth, delayed teeth eruption, narrow or high palate)	
 Neurological examination	
  Cranial nerves (e.g., extraocular muscle movement, lack of facial expressions, poor facial movement)	
  Motor (assessing the muscle bulk, tone, and strength, e.g., hyperhypotonia, muscle wasting, or fasciculation)	
  Reflexes (e.g., hyper-hyporeflexia, clonus, Babinski)	
  Coordination/gait (e.g., ataxic, or tandem gait)	
  Sensory (e.g., paresthesia and dysesthesia)	
 Systemic examination	
  Abdomen/cardiac (e.g., organomegaly, umbilical or inguinal hernia, heart sounds)	
  External genitalia (e.g., large testes)	
GDD, global developmental delay; ID, intellectual disability; NICU, neonatal intensive care unit.

Table 3. Recent studies highlighting genetic significance of assessing individuals with GDD/ID

Method	Study	No. of subjects	Diagnostic yield (%)	Cohort phenotype	
CMA	Liu et al. (2022) [32]	251	32	Unexplained DD/ID	
Wang et al. (2019) [33]	358	25	Unexplained DD/ID	
Leite et al. (2022) [30]	83	21.7	GDD/ID +/− MCA	
Yuan et al. (2021) [34]	2,688	21	Nonsyndromic DD/ID	
Kamath et al. (2022) [35]	67	21	GDD/ID +/− comorbidities	
Gene panel	Leite et al. (2022) [30]	19	63	GDD/ID +/− MCA	
Ibarluzea et al. (2020) [36]	47	26	Unexplained GDD/ID	
Pekeles et al. (2019) [37]	48	21	GDD/ID	
WES	Nouri et al. (2021) [38]	61	66	Unexplained DD/ID	
Hiraide et al. (2021) [39]	101	54	Unexplained DD/ID	
Jo et al. (2024) [40]	41	48.8	Unexplained DD/ID	
Ballesta-Martínez et al. (2023) [41]	188	34	Unexplained ID	
Alotibi et al. (2023) [42]	105	30	NDDs	
WGS	Zahir et al. (2021) [43]	8	63	Moderate-severe ID with brain malformation	
Lee et al (2021) [44]	73	41.1	NDDs	
Abe-Hatano et al. (2022) [45]	45	24	ID	
Sun et al. (2022) [31]	100	21	Unexplained DD/ID	
GDD, global developmental delay; ID, intellectual disability; CMA, chromosome microarray; MCA, multiple congenital anomaly; DD, developmental delay; WES, whole-exome sequencing; WGS, whole-genome sequencing; NDD, neurodevelopmental disorder.

Table 4. Comprehensive workup of children with GDD/ID

Blood	
 Complete blood count, electrolytes, basic chemistry, lipid panel, iron, creatinine kinase enzyme, thyroid function tests, liver function tests, plasma amino acids, ammonia, lactic acid, serum lactate/pyruvate, capillary blood gas, and lysosomal enzymes, uric acid level, lead level, homocysteine, very longchain fatty acids, transferring, copper, ceruloplasmin level, acylcarnitine levels, cholesterol and 7-dehydrocholesterol, biotinides, white cell lysosomal enzymes, plasmalogens, pipecolic acid and phytanic acid, cholestanol, and prolidase	
Urine	
 Organic acids, glycosaminoglycans, sialic acids, purine, urea, pyrimidines, creatine oligosaccharides, sulfite, succinyl purines, and guanidinoacetate	
Cerebrospinal fluid (CSF)	
 Glucose (including CSF to plasma glucose ratio), glycine (including CSF glycine to plasma glycine ratio), lactate, pyruvate, and neurotransmitters	
Congenital infections	
 Toxoplasma, rubella, CMV, others (HBV, HIV), and herpesvirus screening	
Neuroimaging	
 MRI/MRS, CT scan, and US	
Neurophysiology	
 Electroencephalogram, nerve conduction study, and electromyography	
Visual and hearing assessment	
 Funduscopic examination, testing visual field and acuity, visual evoked potentials, behavioral observation audiometry, and brainstem auditory-evoked	
Genetic	
 Standard karyotype	
 FMR1 and MECP2 testing	
 Chromosomal microarray	
 Methylation tests at imprinted chromosomal loci, including methylation-specific MLPA tests for Prader-Willi and Angelman syndromes	
 Whole-exome sequencing	
 Whole-genome sequencing	
GDD, global developmental delay; ID, intellectual disability; CMV, cytomegalovirus; HBV, hepatitis B virus; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; CT, computed tomography; US, ultrasonography; MLPA, multiplex ligation-dependent probe amplification.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
==== Refs
References

1 Diagnostic and Statistical Manual of Mental Disorders (DSM5) [Internet]. Washington, DC; American Psychiatric Association Publishing; [2024 Fe 17]. Available from: 10.1176/appi.books.9780890425596
2 Khan I, Leventhal BL. Developmental delay. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [updated 2023 Jul 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562231/
3 Nair R Chen M Dutt AS Hagopian L Singh A Du M Significant regional inequalities in the prevalence of intellectual disability and trends from 1990 to 2019: a systematic analysis of GBD 2019 Epidemiol Psychiatr Sci 2022 31 e91 36539341
4 Masri AT Oweis L Ali M Hamamy H Global developmental delay and intellectual disability in the era of genomics: diagnosis and challenges in resource-limited areas Clin Neurol Neurosurg 2023 230 107799 37236004
5 Sachdeva P Sitaraman S Minocha P Jain RS Choudhary A Jetha K Etiological profile of children with global developmental delay: a single center study J Pediatr Neurol 2018 17 111 7
6 Choo YY Agarwal P How CH Yeleswarapu SP Developmental delay: identification and management at primary care level Singapore Med J 2019 60 119 23 30997518
7 Lee K, Cascella M, Marwaha R. Intellectual disability. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [updated 2023 Jun 4]. Available from:https://www.ncbi.nlm.nih.gov/books/NBK547654/
8 Riou EM Ghosh S Francoeur E Shevell MI Global developmental delay and its relationship to cognitive skills Dev Med Child Neurol 2009 51 600 6 19627332
9 Stadskleiv K Cognitive functioning in children with cerebral palsy Dev Med Child Neurol 2020 62 283 9 32010976
10 AlMutiri R Malta M Shevell MI Srour M Evaluation of individuals with non-syndromic global developmental delay and intellectual disability Children 2023 10 414 36979972
11 Almahmoud OH Abushaikha L Prevalence and risk factors of developmental disabilities among preschool children in the Arab world: a narrative literature review Child Health Nurs Res 2023 29 101 10 37170489
12 Bélanger SA Caron J Evaluation of the child with global developmental delay and intellectual disability Paediatr Child Health 2018 23 403 19 30919832
13 Miclea D Peca L Cuzmici Z Pop IV Genetic testing in patients with global developmental delay/intellectual disabilities. A review Clujul Med 2015 88 288 92 26609258
14 Eun SH Hahn SH Metabolic evaluation of children with global developmental delay Korean J Pediatr 2015 58 117 22 25932032
15 Chen B Zhan Y Kessi M Chen S Xiong J Deng X Urine organic acids as metabolic indicators for global developmental delay/intellectual disability in chinese children Front Mol Biosci 2021 8 792319 35036412
16 Rezaeinejad M Riahi SM Moghadam KB Tadi MJ Geraili Z Parsa H The association between maternal infection and intellectual disability in children: a systematic review and meta-analysis PLoS One 2023 18 e0292226 37796792
17 Vasudevan P Suri M A clinical approach to developmental delay and intellectual disability Clin Med (Lond) 2017 17 558 61 29196358
18 Chen S Zhao S Dalman C Karlsson H Gardner R Association of maternal diabetes with neurodevelopmental disorders: autism spectrum disorders, attention-deficit/hyperactivity disorder and intellectual disability Int J Epidemiol 2021 50 459 74 33221916
19 Cohen JS Genetic counseling in neurodevelopmental disorders Cold Spring Harb Perspect Med 2020 10 a036533 31501260
20 Misirliyan SS, Boehning AP, Shah M. Development milestones. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [updated 2023 Mar 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557518/
21 Freeman AJ Chen YL Interpreting pediatric intelligence tests: a framework from evidence-based medicine Goldstein G Allen DN DeLuca J Handbook of psychological assessment 4th ed Cambridge (MA) Academic Press 2019 65 101
22 Jimenez-Gomez A Standridge SM A refined approach to evaluating global developmental delay for the international medical community Pediatr Neurol 2014 51 198 206 25079568
23 Chaves TF Ocampos M Barbato IT de Camargo Pinto LL de Luca GR Barbato Filho JH A cohort study of neurodevelopmental disorders and/or congenital anomalies using high resolution chromosomal microarrays in southern Brazil highlighting the significance of ASD Sci Rep 2024 14 3762 38355898
24 Seggers J Haadsma ML Bos AF Heineman MJ Middelburg KJ van den Heuvel ER Dysmorphic features and developmental outcome of 2-year-old children Dev Med Child Neurol 2014 56 1078 84 25040419
25 Dubay KS, Zach TL. Newborn screening. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan- [updated 2023 May 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558983/
26 Alamri A Aljadhai YI Alrashed A Alfheed B Abdelmoaty R Alenazi S Identifying clinical clues in children with global developmental delay/intellectual disability with abnormal brain magnetic resonance imaging (MRI) J Child Neurol 2021 36 432 9 33295251
27 Rajvanshi N Chacham S Ks A Semwal P Nandolia KK Rohilla J Magnetic resonance imaging brain yield in developmental delay: A developing country perspective Res Dev Disabil 2023 138 104518 37148576
28 Funanage VL Impact of genetic testing on human health: the current landscape and future for personalized medicine Dela J Public Health 2021 7 10 1
29 Julkowska D Austin CP Cutillo CM Gancberg D Hager C Halftermeyer J The importance of international collaboration for rare diseases research: a European perspective Gene Ther 2017 24 562 71 28440796
30 Leite AJDC Pinto IP Leijsten N Ruiterkamp-Versteeg M Pfundt R de Leeuw N Diagnostic yield of patients with undiagnosed intellectual disability, global developmental delay and multiples congenital anomalies using karyotype, microarray analysis, whole exome sequencing from Central Brazil PLoS One 2022 17 e0266493 35390071
31 Sun Y Peng J Liang D Ye X Xu N Chen L Genome sequencing demonstrates high diagnostic yield in children with undiagnosed global developmental delay/intellectual disability: A prospective study Hum Mutat 2022 43 568 81 35143101
32 Liu Y Lv Y Zarrei M Dong R Yang X Higginbotham EJ Chromosomal microarray analysis of 410 Han Chinese patients with autism spectrum disorder or unexplained intellectual disability and developmental delay NPJ Genom Med 2022 7 1 35022430
33 Wang R Lei T Fu F Li R Jing X Yang X Application of chromosome microarray analysis in patients with unexplained developmental delay/intellectual disability in South China Pediatr Neonatol 2019 60 35 42 29631977
34 Yuan H Shangguan S Li Z Luo J Su J Yao R CNV profiles of Chinese pediatric patients with developmental disorders Genet Med 2021 23 669 78 33402738
35 Kamath V Yoganathan S Thomas MM Gowri M Chacko MP Utility of chromosomal microarray in children with unexplained developmental delay/intellectual disability Fetal Pediatr Pathol 2022 41 208 18 32701375
36 Ibarluzea N Hoz AB Villate O Llano I Ocio I Martí I Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability Genes (Basel) 2020 11 51 31906484
37 Pekeles H Accogli A Boudrahem-Addour N Russell L Parente F Srour M Diagnostic yield of intellectual disability gene panels Pediatr Neurol 2019 92 32 6 30581057
38 Nouri N Bahreini A Nasiri J Salehi M Clinical and genetic profile of children with unexplained intellectual disability/developmental delay and epilepsy Epilepsy Res 2021 177 106782 34695666
39 Hiraide T Yamoto K Masunaga Y Asahina M Endoh Y Ohkubo Y Genetic and phenotypic analysis of 101 patients with developmental delay or intellectual disability using whole-exome sequencing Clin Genet 2021 100 40 50 33644862
40 Jo YH Choi SH Yoo HW Kwak MJ Park KH Kong J Clinical use of whole exome sequencing in children with developmental delay/intellectual disability Pediatr Neonatol 2024 Jan 23 S1875-9572(24)00004-4. doi: 10.1016/j.pedneo.2023.05.015. Epub
41 Ballesta-Martínez MJ Pérez-Fernández V López-González V Sánchez-Soler MJ Serrano-Antón AT Rodríguez-Peña LI Validation of clinical exome sequencing in the diagnostic procedure of patients with intellectual disability in clinical practice Orphanet J Rare Dis 2023 18 201 37480025
42 Alotibi RS Sannan NS AlEissa M Aldriwesh MG Al Tuwaijri A Akiel MA The diagnostic yield of CGH and WES in neurodevelopmental disorders Front Pediatr 2023 11 1133789 36937954
43 Zahir FR Mwenifumbo JC Chun HE Lim EL Van Karnebeek CDM Couse M Comprehensive whole genome sequence analyses yields novel genetic and structural insights for Intellectual Disability BMC Genomics 2017 18 403 28539120
44 Lee HF Chi CS Tsai CR Diagnostic yield and treatment impact of whole-genome sequencing in paediatric neurological disorders Dev Med Child Neurol 2021 63 934 8 33244750
45 Abe-Hatano C Iida A Kosugi S Momozawa Y Terao C Ishikawa K Whole genome sequencing of 45 Japanese patients with intellectual disability Am J Med Genet A 2021 185 1468 80 33624935
46 Ko MH Chen HJ Genome-wide sequencing modalities for children with unexplained global developmental delay and intellectual disabilities-a narrative review Children (Basel) 2023 10 501 36980059
47 Çebi AH Altıner Ş Application of chromosome microarray analysis in the investigation of developmental disabilities and congenital anomalies: single center experience and review of NRXN3 and NEDD4L deletions Mol Syndromol 2020 11 197 206 33224013
48 Sadek AA Mohamed MA Yield of karyotyping in children with developmental delay and/or dysmorphic features in Sohag University Hospital, Upper Egypt Egypt J Med Human Genet 2018 19 253 59
49 Srivastava S Love-Nichols JA Dies KA Ledbetter DH Martin CL Chung WK NDD Exome Scoping Review Work Group Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders Genet Med 2019 21 2413 21 31182824
50 Savatt JM Myers SM Genetic testing in neurodevelopmental disorders Front Pediatr 2021 9 526779 33681094
51 Innes J Reali L Clayton-Smith J Hall G Lim DH Burghel GJ CNVs affecting cancer predisposing genes (CPGs) detected as incidental findings in routine germline diagnostic chromosomal microarray (CMA) testing J Med Genet 2018 55 89 96 28918392
52 Stone WL, Basit H, Shah M, Los E. Fragile X syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [updated 2023 Oct 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459243/
53 Borch LA Parboosingh J Thomas MA Veale P Re-evaluating the first-tier status of fragile X testing in neurodevelopmental disorders Genet Med 2020 22 1036 9 32152462
54 Chahil G, Bollu PC. Rett syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [updated 2023 Aug 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482252/
55 Petriti U Dudman DC Scosyrev E Lopez-Leon S Global prevalence of Rett syndrome: systematic review and meta-analysis Syst Rev 2023 12 5 36642718
56 Inuzuka LM Guerra-Peixe M Macedo-Souza LI Pedreira CC Gurgel-Giannetti J Monteiro FP MECP2-related conditions in males: A systematic literature review and 8 additional cases Eur J Paediatr Neurol 2021 34 7 13 34271245
57 Aldosary M Al-Bakheet A Al-Dhalaan H Almass R Alsagob M Al-Younes B Rett Syndrome, a Neurodevelopmental Disorder, Whole-Transcriptome, and Mitochondrial Genome Multiomics Analyses Identify Novel Variations and Disease Pathways OMICS 2020 24 160 71 32105570
58 Han JY Lee IG Genetic tests by next-generation sequencing in children with developmental delay and/or intellectual disability Clin Exp Pediatr 2020 63 195 202 32024334
59 Corominas J Smeekens SP Nelen MR Yntema HG Kamsteeg EJ Pfundt R Clinical exome sequencing-Mistakes and caveats Hum Mutat 2022 43 1041 55 35191116
60 Manickam K McClain MR Demmer LA Biswas S Kearney HM Malinowski J Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) Genet Med 2021 23 2029 37 34211152
61 Lionel AC Costain G Monfared N Walker S Reuter MS Hosseini SM Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test Genet Med 2018 20 435 43 28771251
62 Bertoli-Avella AM Beetz C Ameziane N Rocha ME Guatibonza P Pereira C Successful application of genome sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort Eur J Hum Genet 2021 29 141 53 32860008
63 van Slobbe M van Haeringen A Vissers LELM Bijlsma EK Rutten JW Suerink M Reanalysis of whole-exome sequencing (WES) data of children with neurodevelopmental disorders in a standard patient care context Eur J Pediatr 2024 183 345 55 37889289
64 Costain G Jobling R Walker S Reuter MS Snell M Bowdin S Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing Eur J Hum Genet 2018 26 740 4 29453418
65 Kim SW Jeon HR Jung HJ Kim JA Song JE Kim J Clinical Characteristics of Developmentally Delayed Children based on Interdisciplinary Evaluation Sci Rep 2020 10 8148 32424178
66 Kishore MT Udipi GA Seshadri SP Clinical practice guidelines for assessment and management of intellectual disability Indian J Psychiatry 2019 61(Suppl 2) 194 210 30745696
67 Dong P Xu Q Zhang Y Li DY Zhou BR Hu CC A multicenter clinical study on parent-implemented early intervention for children with global developmental delay Front Pediatr 2023 11 1052665 36873631
68 Smythe T Zuurmond M Tann CJ Gladstone M Kuper H Early intervention for children with developmental disabilities in low and middle-income countries - the case for action Int Health 2021 13 222 31 32780826
69 Jhuo RA Chu SY A review of parent-implemented early start denver model for children with autism spectrum disorder Children 2022 9 285 35205005
70 Reddihough D Leonard H Jacoby P Kim R Epstein A Murphy N Comorbidities and quality of life in children with intellectual disability Child Care Health Dev 2021 47 654 66 33885172
71 Burns J Phung R McNeill S Hanlon-Dearman A Ricci MF Comorbidities affecting children with autism spectrum disorder: a retrospective chart review Children (Basel) 2023 10 1414 37628413
72 Alenezi S Alkhiri A Hassanin W AlHarbi A Al Assaf M Alzunaydi N Findings of a Multidisciplinary Assessment of Children Referred for Possible Neurodevelopmental Disorders: Insights from a Retrospective Chart Review Study Behav Sci (Basel) 2022 12 509 36546992
73 Shevell M The role of the pediatric neurologist in the care of children with neurodevelopmental disabilities Pediatr Neurol 2018 88 3 9 30318285
74 Hoytema van Konijnenburg EMM Wortmann SB Koelewijn MJ Tseng LA Houben R Stöckler-Ipsiroglu S Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app Orphanet J Rare Dis 2021 16 170 33845862
75 Srour M AlHakeem A Shevell M Global developmental delay and intellectual disability Rosenberg RN Pascual JM Rosenberg’s molecular and genetic basis of neurological and psychiatric disease 6th ed Cambridge (MA) Academic Press 2020 269 81
76 Turner TJ Zourray C Schorge S Lignani G Recent advances in gene therapy for neurodevelopmental disorders with epilepsy J Neurochem 2021 157 229 62 32880951
77 Ozlu C Bailey RM Sinnett S Goodspeed KD Gene transfer therapy for neurodevelopmental disorders Dev Neurosci 2021 43 230 40 33882495
